Advertisement
Screener

REPLIGEN CORP (RGEN) Operating Cash Flow

2.8 / 5 stars · 68/120 Roast Me

REPLIGEN CORP Operating Cash Flow

REPLIGEN CORP (RGEN) reported Operating Cash Flow of $61.06 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-29.

Financial Statements › Cash Flow › Operating Activities

us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-07-29

  • REPLIGEN CORP net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was $32.77M, a 14.53% increase year-over-year.
  • REPLIGEN CORP net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was $28.30M, a 88.57% increase year-over-year.
  • REPLIGEN CORP net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was $25.70M, a 34.39% decline year-over-year.
  • REPLIGEN CORP net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was $48.10M, a 2.48% decline year-over-year.
  • REPLIGEN CORP net cash provided by (used in) operating activities for fiscal 2025 was $117.42M, a 33.06% decline from fiscal 2024.
  • REPLIGEN CORP net cash provided by (used in) operating activities for fiscal 2024 was $175.39M, a 53.97% increase from fiscal 2023.
  • REPLIGEN CORP net cash provided by (used in) operating activities for fiscal 2023 was $113.92M, a 33.80% decline from fiscal 2022.
  • REPLIGEN CORP net cash provided by (used in) operating activities for fiscal 2022 was $172.08M, a 44.59% increase from fiscal 2021.
Period endNet Cash Provided by (Used in) Operating Activities 3 monthNet Cash Provided by (Used in) Operating Activities 6 monthNet Cash Provided by (Used in) Operating Activities 9 monthNet Cash Provided by (Used in) Operating Activities 12 month
2026-06-30$32.77M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-29
$61.06M
10-Q · filed 2026-07-29
$86.77M
derived: sum of 3 quarters · filed 2026-07-29
$134.86M
derived: sum of 4 quarters · filed 2026-07-29
2026-03-31$28.30M
10-Q · filed 2026-05-06
$54.00M
derived: sum of 2 quarters · filed 2026-05-06
$102.10M
derived: sum of 3 quarters · filed 2026-05-06
$130.71M
derived: sum of 4 quarters · filed 2026-07-29
2025-12-31$25.70M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26
$73.80M
derived: sum of 2 quarters · filed 2026-02-26
$102.41M
derived: sum of 3 quarters · filed 2026-07-29
$117.42M
10-K · filed 2026-02-26
2025-09-30$48.10M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04
$76.71M
derived: sum of 2 quarters · filed 2026-07-29
$91.71M
10-Q · filed 2025-11-04
$130.89M
derived: sum of 4 quarters · filed 2026-07-29
2025-06-30$28.61M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-29
$43.61M
10-Q · filed 2026-07-29
$82.79M
derived: sum of 3 quarters · filed 2026-07-29
$132.11M
derived: sum of 4 quarters · filed 2026-07-29
2025-03-31$15.01M
10-Q · filed 2026-05-06
$54.18M
derived: sum of 2 quarters · filed 2026-05-06
$103.50M
derived: sum of 3 quarters · filed 2026-05-06
$145.69M
derived: sum of 4 quarters · filed 2026-05-06
2024-12-31$39.18M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26
$88.50M
derived: sum of 2 quarters · filed 2026-02-26
$130.69M
derived: sum of 3 quarters · filed 2026-02-26
$175.39M
10-K · filed 2026-02-26
2024-09-30$49.32M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04
$91.51M
derived: sum of 2 quarters · filed 2025-11-04
$136.22M
10-Q · filed 2025-11-04
$165.28M
derived: sum of 4 quarters · filed 2026-02-26
2024-06-30$42.19M
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07
$86.90M
10-Q · filed 2025-08-07
$115.96M
derived: sum of 3 quarters · filed 2026-02-26
$155.19M
derived: sum of 4 quarters · filed 2026-02-26
2024-03-31$44.71M
10-Q · filed 2025-04-29
$73.77M
derived: sum of 2 quarters · filed 2026-02-26
$113.00M
derived: sum of 3 quarters · filed 2026-02-26
$147.47M
derived: sum of 4 quarters · filed 2026-02-26
2023-12-31$29.07M
derived: 10-K 12 month − 10-Q/A 9 month · filed 2026-02-26
$68.30M
derived: sum of 2 quarters · filed 2026-02-26
$102.76M
derived: sum of 3 quarters · filed 2026-02-26
$113.92M
10-K · filed 2026-02-26
2023-09-30$39.23M
derived: 10-Q/A 9 month − 10-Q/A 6 month · filed 2024-11-18
$73.70M
derived: sum of 2 quarters · filed 2024-11-18
$84.85M
10-Q/A · filed 2024-11-18
$146.74M
derived: sum of 4 quarters · filed 2025-03-14
2023-06-30$34.47M
derived: 10-Q/A 6 month − 10-Q/A 3 month · filed 2024-11-18
$45.62M
10-Q/A · filed 2024-11-18
$107.50M
derived: sum of 3 quarters · filed 2025-03-14
$148.87M
derived: sum of 4 quarters · filed 2025-03-14
2023-03-31$11.15M
10-Q/A · filed 2024-11-18
$73.04M
derived: sum of 2 quarters · filed 2025-03-14
$114.40M
derived: sum of 3 quarters · filed 2025-03-14
$160.12M
derived: sum of 4 quarters · filed 2025-03-14
2022-12-31$61.88M
derived: 10-K 12 month − 10-Q/A 9 month · filed 2025-03-14
$103.25M
derived: sum of 2 quarters · filed 2025-03-14
$148.97M
derived: sum of 3 quarters · filed 2025-03-14
$172.08M
10-K · filed 2025-03-14
2022-09-30$41.37M
derived: 10-Q/A 9 month − 10-Q/A 6 month · filed 2024-11-18
$87.09M
derived: sum of 2 quarters · filed 2024-11-18
$110.20M
10-Q/A · filed 2024-11-18
$159.82M
derived: sum of 4 quarters · filed 2024-11-18
2022-06-30$45.72M
derived: 10-Q/A 6 month − 10-Q/A 3 month · filed 2024-11-18
$68.83M
10-Q/A · filed 2024-11-18
$118.45M
derived: sum of 3 quarters · filed 2024-11-18
$140.94M
derived: sum of 4 quarters · filed 2024-11-18
2022-03-31$23.11M
10-Q/A · filed 2024-11-18
$72.73M
derived: sum of 2 quarters · filed 2024-11-18
$95.22M
derived: sum of 3 quarters · filed 2024-11-18
$132.87M
derived: sum of 4 quarters · filed 2024-11-18
2021-12-31$49.62M
derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-11-18
$72.10M
derived: sum of 2 quarters · filed 2024-11-18
$109.75M
derived: sum of 3 quarters · filed 2024-11-18
$119.02M
10-K/A · filed 2024-11-18
2021-09-30$22.48M
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-01
$60.13M
derived: sum of 2 quarters · filed 2022-11-01
$69.40M
10-Q · filed 2022-11-01
$84.27M
derived: sum of 4 quarters · filed 2023-02-22
2021-06-30$37.65M
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-02
$46.91M
10-Q · filed 2022-08-02
$61.78M
derived: sum of 3 quarters · filed 2023-02-22
$83.27M
derived: sum of 4 quarters · filed 2023-02-22
2021-03-31$9.26M
10-Q · filed 2022-04-27
$24.13M
derived: sum of 2 quarters · filed 2023-02-22
$45.62M
derived: sum of 3 quarters · filed 2023-02-22
$62.36M
derived: sum of 4 quarters · filed 2023-02-22
2020-12-31$14.87M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-22
$36.36M
derived: sum of 2 quarters · filed 2023-02-22
$53.09M
derived: sum of 3 quarters · filed 2023-02-22
$62.63M
10-K · filed 2023-02-22
2020-09-30$21.49M
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-10-28
$38.22M
derived: sum of 2 quarters · filed 2021-10-28
$47.75M
10-Q · filed 2021-10-28
$65.43M
derived: sum of 4 quarters · filed 2022-02-17
2020-06-30$16.73M
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-27
$26.27M
10-Q · filed 2021-07-27
$43.94M
derived: sum of 3 quarters · filed 2022-02-17
$65.90M
derived: sum of 4 quarters · filed 2022-02-17
2020-03-31$9.53M
10-Q · filed 2021-05-04
$27.20M
derived: sum of 2 quarters · filed 2022-02-17
$49.17M
derived: sum of 3 quarters · filed 2022-02-17
$66.96M
derived: sum of 4 quarters · filed 2022-02-17
2019-12-31$17.67M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-17
$39.64M
derived: sum of 2 quarters · filed 2022-02-17
$57.43M
derived: sum of 3 quarters · filed 2022-02-17
$67.22M
10-K · filed 2022-02-17
2019-09-30$21.96M
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05
$39.75M
derived: sum of 2 quarters · filed 2020-11-05
$49.54M
10-Q · filed 2020-11-05
$55.10M
derived: sum of 4 quarters · filed 2021-02-24
2019-06-30$17.79M
derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-30
$27.58M
10-Q · filed 2020-07-30
$33.13M
derived: sum of 3 quarters · filed 2021-02-24
$52.81M
derived: sum of 4 quarters · filed 2021-02-24
2019-03-31$9.79M
10-Q · filed 2020-05-06
$15.34M
derived: sum of 2 quarters · filed 2021-02-24
$35.02M
derived: sum of 3 quarters · filed 2021-02-24
$40.99M
derived: sum of 4 quarters · filed 2021-02-24
2018-12-31$5.55M
derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-24
$25.23M
derived: sum of 2 quarters · filed 2021-02-24
$31.20M
derived: sum of 3 quarters · filed 2021-02-24
$32.77M
10-K · filed 2021-02-24
2018-09-30$19.68M
derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-31
$25.64M
derived: sum of 2 quarters · filed 2019-10-31
$27.21M
10-Q · filed 2019-10-31
$42.43M
derived: sum of 4 quarters · filed 2020-02-26
2018-06-30$5.96M
derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-01
$7.54M
10-Q · filed 2019-08-01
$22.75M
derived: sum of 3 quarters · filed 2020-02-26
$21.02M
derived: sum of 4 quarters · filed 2020-02-26
2018-03-31$1.57M
10-Q · filed 2019-05-09
$16.79M
derived: sum of 2 quarters · filed 2020-02-26
$15.06M
derived: sum of 3 quarters · filed 2020-02-26
2017-12-31$15.22M
derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-26
$13.49M
derived: sum of 2 quarters · filed 2020-02-26
$17.45M
10-K · filed 2020-02-26
2017-09-30-$1.73M
derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-01
$2.23M
10-Q · filed 2018-11-01
2017-06-30$3.96M
10-Q · filed 2018-08-02
2016-12-31$7.52M
10-K · filed 2019-03-01
2013-12-31$7.34M
derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-14
$13.54M
derived: sum of 2 quarters · filed 2014-03-14
$22.34M
derived: sum of 3 quarters · filed 2014-03-14
$25.93M
10-K · filed 2014-03-14
2013-09-30$6.20M
derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-08
$15.00M
derived: sum of 2 quarters · filed 2013-11-08
$18.59M
10-Q · filed 2013-11-08
$25.82M
derived: sum of 4 quarters · filed 2014-03-14
2013-06-30$8.80M
derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-07
$12.39M
10-Q · filed 2013-08-07
$19.62M
derived: sum of 3 quarters · filed 2014-03-14
$22.09M
derived: sum of 4 quarters · filed 2014-03-14
2013-03-31$3.59M
10-Q · filed 2013-05-07
$10.82M
derived: sum of 2 quarters · filed 2014-03-14
$13.30M
derived: sum of 3 quarters · filed 2014-03-14
$15.30M
derived: sum of 4 quarters · filed 2014-03-14
2012-12-31$7.23M
derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-14
$9.70M
derived: sum of 2 quarters · filed 2014-03-14
$11.71M
derived: sum of 3 quarters · filed 2014-03-14
$13.44M
10-K · filed 2014-03-14
2012-09-30$2.47M
derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-08
$4.48M
derived: sum of 2 quarters · filed 2013-11-08
$6.21M
10-Q · filed 2013-11-08
$11.08M
derived: sum of 4 quarters · filed 2014-03-14
2012-06-30$2.01M
derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-07
$3.74M
10-Q · filed 2013-08-07
$8.61M
derived: sum of 3 quarters · filed 2014-03-14
$8.76M
derived: sum of 4 quarters · filed 2014-03-14
2012-03-31$1.73M
10-Q · filed 2013-05-07
$6.61M
derived: sum of 2 quarters · filed 2014-03-14
$6.76M
derived: sum of 3 quarters · filed 2014-03-14
$4.04M
derived: sum of 4 quarters · filed 2014-03-14
2011-12-31$4.87M
derived: 10-K 9 month − 10-Q 6 month · filed 2014-03-14
$5.02M
derived: sum of 2 quarters · filed 2014-03-14
$2.31M
10-K · filed 2014-03-14
$3.75M
derived: sum of 4 quarters · filed 2014-03-14
2011-09-30$148.09K
derived: 10-Q 6 month − 10-Q 3 month · filed 2011-11-09
-$2.56M
10-Q · filed 2011-11-09
-$1.12M
10-Q · filed 2012-11-08
-$4.47K
derived: sum of 4 quarters · filed 2014-03-14
2011-06-30-$2.71M
10-Q · filed 2011-08-05
-$1.27M
10-Q · filed 2012-08-09
-$152.56K
derived: sum of 3 quarters · filed 2014-03-14
$982.52K
derived: sum of 4 quarters · filed 2014-03-14
2011-03-31$1.44M
10-Q · filed 2012-05-10
$2.56M
derived: sum of 2 quarters · filed 2014-03-14
$3.69M
derived: sum of 3 quarters · filed 2014-03-14
$3.23M
10-K · filed 2013-03-15
2010-12-31$1.11M
derived: 10-K 9 month − 10-Q 6 month · filed 2014-03-14
$2.25M
derived: sum of 2 quarters · filed 2014-03-14
$1.79M
10-K · filed 2014-03-14
2010-09-30$1.14M
derived: 10-Q 6 month − 10-Q 3 month · filed 2011-11-09
$673.73K
10-Q · filed 2011-11-09
2010-06-30-$461.36K
10-Q · filed 2011-08-05
2010-03-31-$2.45M
10-K · filed 2012-03-15

Similar stocks

Stock NameCountryMarket CapPE Ratio
Krystal Biotech, Inc. (KRYS)United States$10.210B45.56
BIO-TECHNE Corp (TECH)United States$11.379B74.68
Twist Bioscience Corp (TWST)United States$11.540B-47.21
Kymera Therapeutics, Inc. (KYMR)United States$9.631B-31.69
ImmunityBio, Inc. (IBRX)United States$9.157B-9.29
Vaxcyte, Inc. (PCVX)United States$8.466B-7.91
HALOZYME THERAPEUTICS, INC. (HALO)United States$13.083B21.59
NEUROCRINE BIOSCIENCES INC (NBIX)United States$14.131B24.25
EXELIXIS, INC. (EXEL)United States$14.358B16.15
Immunovant, Inc. (IMVT)United States$7.028B-14.78